Ocular Therapeutix (OCUL) EBITDA Margin (2014 - 2026)

Ocular Therapeutix's EBITDA Margin history runs 13 years deep, the most recent figure standing at 865.46% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 26799.0% year-over-year to 865.46% in Q1 2026; TTM through Mar 2026 was 575.42%, a 23327.0% decrease from a year earlier, with the FY2025 full-year figure at 519.75%, down 25018.0% from the prior year.
• EBITDA Margin retreated to 865.46% in Q1 2026 per OCUL's latest filing, from 526.49% in the prior quarter.
• Across five years, EBITDA Margin topped out at 127.41% in Q3 2023 and bottomed at 865.46% in Q1 2026.
• The 5-year median for EBITDA Margin is 214.0% (2024), against an average of 307.05%.
• Across the five-year window, EBITDA Margin soared 14028 bps in 2022 and sank 38346 bps in 2025, its largest moves.
• Year by year, EBITDA Margin stood at 137.56% in 2022, then grew by 2 bps to 135.46% in 2023, then sank by 119 bps to 296.08% in 2024, then sank by 78 bps to 526.49% in 2025, then sank by 64 bps to 865.46% in 2026.
• Per Business Quant, the three latest OCUL EBITDA Margin figures stand at 865.46% (Q1 2026), 526.49% (Q4 2025), and 472.35% (Q3 2025).